|
|
|
| Efficacy of elagolix for alleviating pain of women with moderate or severe endometriosis and its influence on their peripheral blood pain stress factors levels |
| 1.Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, 310053；2. The first People's Hospital of Huzhou, Zhejiang Province |
|
|
|
|
Abstract To observe the curative effect of elagolix for alleviating pain of women with moderate or severe endometriosis, and to study its influence on the peripheral blood pain stress factors levels of the women. Methods: 80 women with moderate or severe pain related endometriosis were selected and were randomly divided into two groups from January to December 2020. 39 women in the observation group had received elagoli treatment for 3 months, and 41 women in the observation group had received placebo for 3 months. The scores of dysmenorrhea, non-menstrual pelvic pain, pain during intercourse, and digital analog scale (NRS) of the women before and after treatment were compared between the two groups. The value of bone mineral density (BMD) of lumbar spine L1-4 and femoral neck of the women in the two groups were measured, and the levels of serum pain stress factor prostaglandin E2 (PGE2) and nerve growth factor (NGF) of the women in the two groups were detected. Results: After 3 months of treatment, the scores of dysmenorrhea (1.44±0.38 points), non-menstrual pelvic pain (1.25±0.33 points), and pain during intercourse (1.19±0.39 points), and NRS (3.12±0.72 points) of the women in the observation group were significantly lower than those (1.81±0.41 points, 1.44±0.46 points, 1.41±0.42 points, and 5.01±1.01 points) of the women in the control group, and the rate of pain reduction with clinical significance of the women in the observation group was significantly higher than that of the women in the control group (P<0.05). The levels of PGE2 and NGF of the women in the two groups had decreased significantly, and which (249.71±33.05 pg/ml and 167.43±51.27 pg/ml) of the women in the observation group were significantly lower than those (589.92±132.51 pg/ml and 301.43±90.23 pg/ml) of the women in the control group (P<0.05). The BMD value of the women in the two groups after treatment had no significant different from that before treatment (P>0.05). The incidences of hot flashes (25.6%) and total incidence (84.6%) of the women in the observation group were significantly higher than those (7.3% and 56.1%) of the women in the control group (P<0.05). Conclusion: Elagolix for alleviating pain of women with moderate or severe endometriosis has significant effectiveness, especially for alleviating their dysmenorrhea and nonmenstrual pelvic pain, and which can reduce the levels of serum pain stress factors with less adverse influence on the BMD value of these women.
|
|
|
|
|
|
|
|
|
